rna
interfer
rnai
process
doublestrand
rna
induc
posttranscript
sequencespecif
degrad
homolog
messeng
rna
present
studi
carri
appli
rnai
technolog
inhibit
replic
felin
immunodefici
viru
fiv
four
small
interf
rna
sirna
homolog
fiv
gag
gene
synthes
transfect
felin
fibroblast
cell
line
chronic
infect
fiv
crfkfiv
synthet
sirna
effici
inhibit
replic
fiv
next
examin
effect
retrovir
vectormedi
transfer
fivspecif
short
hairpin
rna
shrna
replic
fiv
felin
tcell
line
chronic
infect
fiv
retrovir
vectormedi
transfer
fivspecif
shrna
shown
markedli
inhibit
replic
fiv
cell
result
provid
use
inform
develop
rnaibas
gene
therapi
strategi
control
fiv
infect
felin
immunodefici
viru
fiv
belong
genu
lentiviru
famili
retrovirida
fiv
first
isol
unit
state
report
induc
crucial
immunodefici
infect
cat
similar
human
immunodefici
viru
hiv
infect
peopl
pedersen
et
al
fiv
wide
spread
among
domest
cat
throughout
world
includ
europ
unit
state
australia
vietnam
taiwan
japan
ishida
et
al
lin
et
al
malik
et
al
nakamura
et
al
steinrigl
klein
yamamoto
et
al
fivinfect
cat
show
variou
degre
immunolog
impair
result
clinic
symptom
includ
gingiv
wwwelseviercomlocatevetm
veterinari
microbiolog
stomat
upper
respiratori
tract
infect
myelosuppress
opportunist
infect
bendinelli
et
al
pedersen
barlough
shelton
et
al
preval
variou
clinic
outcom
fiv
infect
consid
one
problemat
diseas
small
anim
practic
number
antivir
drug
revers
transcriptas
inhibitor
proteas
inhibitor
shown
inhibit
fiv
replic
experiment
natur
fivinfect
cat
arai
et
al
egberink
et
al
hartmann
et
al
howev
sever
hematolog
side
effect
antivir
drug
insuffici
clinic
improv
fivinfect
cat
also
report
arai
et
al
hartmann
et
al
therefor
effect
antivir
therapi
fivinfect
cat
establish
rna
interfer
rnai
process
sequencespecif
posttranscript
gene
silenc
ptg
trigger
doublestrand
rna
dsrna
homolog
target
transcript
fire
et
al
dsrna
process
rnase
iiilik
enzym
dicer
small
interf
rna
sirna
nucleotid
bernstein
et
al
sirna
form
rnainduc
silenc
complex
risc
lead
degrad
homolog
target
rna
zamor
et
al
introduct
sirna
induc
sequencespecif
gene
silenc
mammalian
cell
elbashir
et
al
recent
studi
demonstr
rnai
exploit
target
varieti
human
virus
includ
polioviru
human
papillomaviru
hepat
c
viru
hcv
hepat
b
viru
hbv
influenza
viru
sever
acut
respiratori
syndrom
sar
coronaviru
ge
et
al
gitlin
et
al
jacqu
et
al
jiang
milner
randal
et
al
shlomai
shaul
wang
et
al
find
indic
rnai
repres
promis
gene
therapeut
approach
control
viral
infect
import
problem
sirna
low
effici
transfect
primari
cell
transient
inhibitori
effect
elbashir
et
al
contrast
endogen
express
short
hairpin
rna
shrna
mediat
viral
vector
shown
induc
persist
sequencespecif
gene
silenc
varieti
primari
cell
well
experiment
anim
rubinson
et
al
xia
et
al
use
rnai
technolog
strategi
gene
therapi
control
fiv
infect
develop
effect
deliveri
method
sirna
felin
lymphoid
cell
achiev
sustain
inhibitori
effect
requir
lentiviru
vector
recogn
effici
deliveri
method
nondivid
primari
cell
howev
use
clinic
practic
safeti
lentiviru
vectormedi
gene
transfer
fulli
establish
hand
retroviru
vector
appli
sever
human
gene
therapi
clinic
trial
edelstein
et
al
number
report
indic
therapeut
effect
retroviru
vectormedi
transfer
antivir
gene
hivinfect
peopl
deek
et
al
wongstaal
et
al
studi
investig
potenti
rnai
therapeut
strategi
control
fiv
infect
first
examin
effect
chemic
synthes
sirna
homolog
fiv
gag
gene
replic
fiv
chronic
fivinfect
fibroblast
cell
next
deliv
fivspecif
shrna
felin
lymphoid
cell
effici
achiev
persist
inhibitori
effect
replic
fiv
cell
gener
fivspecif
shrna
express
retroviru
vector
examin
effect
replic
fiv
chronic
fivinfect
tcell
line
felin
fibroblast
cell
line
crfk
chronic
infect
fiv
petaluma
strain
crfkfiv
maintain
dulbecco
modifi
eagl
medium
dmem
sigma
st
loui
mo
contain
heatinactiv
fetal
calf
serum
fc
penicillin
streptomycin
felin
tcell
line
chronic
infect
fiv
petaluma
strain
maintain
rpmi
medium
sigma
supplement
heatinactiv
fc
penicillinstreptomycin
design
sirna
base
gener
guidelin
elbashir
et
al
four
sirna
correspond
gag
gene
petaluma
olmst
et
al
genbank
access
number
chosen
highli
conserv
sequenc
fiv
gag
gene
kakinuma
et
al
synthes
dharmacon
research
lafayett
co
sirna
luc
correspond
code
sequenc
firefli
luciferas
purchas
dharmacon
research
use
control
sequenc
sens
antisens
strand
sirna
target
fiv
gag
gene
shown
tabl
sirna
strand
deprotect
anneal
accord
manufactur
instruct
crfkfiv
cell
trypsin
plate
cell
per
well
cm
sixwel
plate
h
prior
sirna
transfect
dmem
contain
fc
without
antibiot
cation
lipid
complex
prepar
incub
appropri
amount
indic
sirna
mm
ml
oligofectamin
invitrogen
rockvil
md
ml
optimemi
medium
invitrogen
min
ad
well
final
volum
ml
incub
h
cell
wash
cultur
dmem
contain
fc
experi
murin
leukemia
viru
mlv
base
vector
psirenretroq
bd
clontech
palo
alto
ca
contain
human
rna
polymeras
iii
promot
drive
express
shrna
puromycin
resist
gene
express
cassett
use
studi
shrna
oligonucleotid
design
contain
sens
strand
sequenc
follow
short
spacer
ttcaagaga
revers
complement
sens
strand
six
thymidin
rna
polymeras
iii
transcript
stop
signal
gener
fiv
gag
genespecif
shrna
two
complementari
dna
oligonucleotid
anneal
insert
bamhi
ecori
site
immedi
downstream
promot
contain
sirna
sequenc
correspond
gag
gene
fiv
petaluma
strain
nt
genom
sequenc
sens
antisens
strand
gatccgccagaaagtaccctagaattcaagagattctagggtactttctggct
aattcaaaaaagccagaaa
gtaccctagaatctcttgaattctagggtactt
respect
neg
control
vector
contain
sirna
sequenc
nonhomolog
mammalian
gene
also
gener
use
sens
oligonucleotid
gatccgt
antisens
oligonucleotid
aattcaaaaaagtgcgttgc
tagtaccaactctcttgaagttggtactagca
rnaireadi
psirenretroq
vector
kit
bd
clontech
construct
verifi
nucleotid
sequenc
vesicular
stomat
viru
envelop
express
plasmid
pvsvg
bd
clontech
use
gener
vector
viru
could
infect
felin
cell
tabl
sequenc
sirna
correspond
region
genom
clone
cell
line
bd
clontech
human
embryon
kidney
deriv
packag
cell
line
stabli
express
gag
pol
gene
mlv
cell
line
cultur
dmem
supplement
heatinactiv
fc
penicillinstreptomycin
mm
lglutamin
mm
sodium
pyruv
gener
vsvg
pseudotyp
mlvbase
shrna
express
retroviru
vector
cell
cm
flask
cotransfect
mixtur
mg
pvsvg
mg
use
cation
lipid
complex
method
lipofectamin
invitrogen
incub
h
medium
remov
cell
wash
phosphat
buffer
salin
pb
cultur
fresh
medium
cultur
supernat
contain
produc
virus
harvest
h
transfect
filtrat
mmpore
size
filter
centrifug
g
min
viral
pellet
resuspend
serumfre
dmem
initi
volum
overnight
aliquot
concentr
virus
store
subsequ
use
concentr
viru
stock
titrat
cell
coloni
form
assay
cell
cell
dmem
contain
heatinactiv
fc
seed
well
cm
sixwel
cultur
plate
incub
h
cell
infect
ml
serial
dilut
viru
stock
presenc
mg
polybren
sigma
per
ml
incub
h
medium
contain
virus
remov
cell
wash
twice
pb
cultur
day
presenc
mg
puromycin
bd
clontech
per
ml
titer
viru
stock
prepar
cfuml
cell
cellswel
seed
well
cm
plate
coat
mg
retronectin
takara
shuzo
kyoto
japan
per
cm
inocul
retroviru
vector
multipl
infect
moi
final
volum
ml
rpmi
medium
contain
heatinactiv
fc
incub
h
cell
wash
twice
pb
cultur
presenc
mg
puromycin
per
ml
day
gener
stabli
transduc
cell
total
cellular
rna
isol
cell
use
guanidin
isothiocyan
method
rneasi
mini
kit
qiagen
valencia
ca
accord
manufactur
protocol
sequenc
primer
probe
use
studi
previous
report
goto
et
al
mizuno
et
al
follow
forward
primer
nucleotid
nt
revers
primer
nt
intern
probe
nt
forward
primer
tgctgtctctgta
nt
felin
bactin
mrna
revers
primer
tgtg
nt
intern
probe
fbatp
nt
probe
label
report
dye
fam
quencher
dye
tamra
end
respect
total
rna
sampl
subject
revers
transcript
polymeras
chain
reaction
pcr
amplif
taqman
gold
rtpcr
kit
appli
biosystem
foster
citi
ca
accord
manufactur
protocol
brief
master
mixtur
contain
reagent
requir
rtpcr
prepar
taqman
buffer
mm
dntp
mm
magnesium
chlorid
u
multiscrib
revers
transcriptas
per
ml
u
rnase
inhibitor
per
ml
u
amplitaq
gold
dna
polymeras
per
ml
total
rna
extract
ng
total
rna
per
tube
ad
master
mixtur
mixtur
use
assay
fiv
rna
bactin
mrna
use
intern
control
give
final
probe
concentr
nm
final
concentr
primer
nm
total
reaction
volum
adjust
ml
target
intern
control
revers
transcrib
min
held
min
activ
amplitaq
gold
subject
pcr
consist
cycl
denatur
annealingpolymer
min
abi
sequenc
detector
appli
biosystem
pcr
cycl
number
threshold
line
repres
c
differ
c
target
c
intern
control
dc
calcul
dc
valu
use
estim
amount
fiv
rna
accord
manufactur
instruct
valu
calcul
give
predict
amount
fiv
rna
comparison
bactin
mrna
ten
microlit
cellfre
cultur
supernat
ad
ml
rt
buffer
contain
mg
poli
sigma
per
ml
mg
oligo
dt
roch
diagnost
indianapoli
per
ml
nonidet
mm
trishcl
mm
kcl
mm
mgcl
mm
edta
mm
dtt
mci
p
dttp
amersham
bioscienc
piscataway
nj
per
ml
incub
h
ml
mixtur
spot
onto
deae
filter
paper
wallac
oy
turku
finland
wash
four
time
ssc
ssc
sodium
chlorid
plu
mm
sodium
citrat
ethanol
filter
paper
dri
incorpor
radioact
filter
paper
measur
autoradiographi
rtactiv
per
ml
cultur
supernat
calcul
valu
incorpor
radioact
per
ml
reaction
mixtur
oneway
analysi
varianc
anova
use
test
signific
differ
rt
activ
cultur
supernat
signific
differ
found
anova
tukeykram
honestli
signific
differ
test
perform
determin
pair
show
differ
statist
signific
defin
p
examin
effect
four
sirna
homolog
gag
gene
fiv
petaluma
clone
replic
fiv
crfkfiv
cell
sirna
homolog
firefli
luciferas
luc
use
control
rt
activ
cultur
supernat
h
transfect
significantli
p
reduc
cell
transfect
compar
mocktransfect
antiluc
sirnatransfect
cell
fig
among
four
antifiv
sirna
show
strongest
inhibitori
effect
replic
fiv
evalu
dosedepend
inhibitori
effect
antifiv
sirna
replic
fiv
examin
effect
replic
fiv
crfkfiv
cell
variou
concentr
transfect
result
signific
p
reduct
amount
fiv
rna
cell
dosedepend
manner
wherea
cell
transfect
lucsirna
concentr
differ
mocktransfect
cell
fig
correspond
reduct
amount
fiv
rna
rt
activ
cultur
supernat
h
transfect
also
reduc
dosedepend
manner
fig
result
indic
sirna
homolog
fiv
gag
gene
could
specif
examin
sever
time
point
rt
activ
cultur
supernat
lowest
h
transfect
reduct
nm
mm
respect
gradual
increas
fig
result
indic
inhibitori
effect
sirna
homolog
fiv
gag
gene
transient
chronic
fivinfect
cell
effect
retroviru
vectormedi
transfer
fivspecif
shrna
replic
fiv
investig
fivinfect
cell
cell
felin
tcell
line
chronic
infect
fiv
petaluma
strain
inocul
vsvg
pseudotyp
retroviru
vector
construct
express
fivspecif
shrna
stabli
shrnaexpress
cell
select
cultiv
presenc
puromycin
replic
fiv
cell
examin
week
inocul
retroviru
vector
amount
fiv
rna
significantli
p
smaller
cell
infect
retroviru
vector
construct
express
shrna
specif
fiv
valu
ae
untreat
cell
ae
cell
infect
control
retroviru
vector
express
shrna
nonhomolog
mammalian
gene
shnc
ae
fig
furthermor
rt
activ
cultur
supernat
also
significantli
p
reduc
cell
infect
retroviru
vector
express
ae
cpmml
compar
untreat
cell
ae
cpmml
cell
infect
retroviru
vector
express
shnc
ae
cpmml
fig
rnai
technolog
consid
new
therapeut
strategi
varieti
viral
infect
human
demonstr
inhibit
replic
virus
achiev
introduct
sirna
shrna
cultur
cell
line
primari
cell
present
studi
carri
demonstr
potenti
rnai
technolog
gene
therapi
strategi
control
fiv
infect
identifi
sequenc
sirna
effici
inhibit
replic
fiv
examin
effect
four
sirna
homolog
fiv
gag
gene
fiv
replic
crfkfiv
cell
demonstr
transfect
antifiv
sirna
result
reduct
rt
activ
cultur
supernat
indic
divers
region
fiv
gag
gene
target
sirna
applic
rnai
technolog
therapeut
purpos
natur
fivinfect
cat
sequenc
divers
fiv
genom
consid
sequenc
use
prepar
effici
inhibit
replic
fiv
studi
highli
conserv
among
variou
strain
fiv
kakinuma
et
al
therefor
highli
plausibl
sirna
inhibit
replic
variou
field
strain
fiva
well
petaluma
strain
howev
sinc
gene
silenc
rnai
requir
almost
perfect
complementar
sirna
target
sequenc
investig
requir
examin
inhibitori
effect
sirna
replic
divers
fiv
strain
studi
show
inhibit
replic
fiv
dosedepend
manner
wherea
lucsirna
result
indic
sirna
homolog
fiv
gag
gene
could
specif
inhibit
replic
fiv
chronic
fivinfect
cell
transfect
higher
concentr
mm
result
inhibit
replic
fiv
wherea
inhibit
lower
concentr
fig
effect
retroviru
vectormedi
transfer
fivspecif
shrna
replic
fiv
cell
cell
infect
retroviru
vector
express
shnc
select
puromycin
amount
fiv
rna
untreat
shnctransduc
cell
rt
activ
cultur
supernat
b
measur
week
retroviru
vectormedi
transduct
amount
fiv
rna
measur
realtim
sequenc
detect
system
rel
fiv
rna
express
valu
calcul
column
bar
show
mean
standard
deviat
respect
obtain
data
triplic
sampl
asterisk
indic
statist
signific
differ
cell
transduc
shnc
p
nm
larg
amount
viral
transcript
would
gener
de
novo
crfkfiv
cell
enough
amount
sirna
might
requir
effici
inhibit
replic
fiv
cell
sirna
transient
transfect
crfkfiv
cell
strongest
inhibitori
effect
viral
replic
observ
h
transfect
effect
gradual
decreas
result
consist
previou
report
describ
silenc
effect
sirna
rapidli
fade
away
continu
divid
mammalian
cell
line
elbashir
et
al
hand
song
et
al
demonstr
inhibit
replic
nondivid
primari
monocytederiv
macrophag
transfect
sirna
target
hiv
sustain
least
day
transfect
song
et
al
crfkfiv
cell
rapidli
prolifer
shortterm
effect
sirna
shown
studi
might
due
dilut
sirna
cell
low
transduct
effici
sirna
cell
transient
effect
import
problem
use
rnai
technolog
strategi
gene
therapi
control
fiv
infect
retroviru
vector
infect
primari
cell
induc
sustain
express
transfer
gene
therefor
examin
effect
retroviru
vectormedi
transfer
shrna
felin
tcell
line
amount
fiv
rna
rt
activ
cultur
supernat
cell
markedli
decreas
even
week
transduct
retroviru
vector
express
shrna
specif
fiv
result
suggest
therapeut
effect
retroviru
vectormedi
deliveri
fivspecif
shrna
cell
infect
fiv
howev
retroviru
vectormedi
fivspecif
shrna
transfer
could
achiev
complet
inhibit
fiv
replic
even
select
antibiot
reason
might
exist
small
number
cell
amount
shrna
enough
inhibit
fiv
replic
even
cell
antibiot
select
anoth
possibl
fiv
clone
escap
shrna
might
exist
cell
clone
cell
line
goal
gene
therapi
strategi
control
fiv
infect
obtain
fivresist
tlymphocyt
howev
transduct
effici
retroviru
vector
use
studi
contain
fluoresc
marker
gene
zsgreen
felin
peripher
blood
mononuclear
cell
moi
wherea
cell
data
shown
investig
necessari
improv
transduct
effici
retroviru
vector
primari
cell
anoth
candid
target
cell
rnai
gene
therapi
control
fiv
infect
hematopoiet
stem
cell
hsc
develop
antivir
gene
therapi
strategi
target
hsc
propos
longterm
treatment
aid
induc
hiv
infect
theori
perman
resist
hiv
infect
achiev
introduct
antivir
gene
pluripot
hsc
capac
selfrenew
well
prolifer
differenti
lymphoid
lineag
recent
hsc
transduc
sirna
construct
direct
hiv
shown
allow
matur
tlymphocyt
vivo
scidhu
mous
thyliv
graft
hscderiv
sirnaexpress
cell
macrophag
show
mark
resist
hiv
infect
banerjea
et
al
although
isol
purif
system
felin
hsc
establish
viral
vectormedi
transfer
antifiv
shrna
hsc
use
gene
therapi
strategi
control
fiv
infect
cat
futur
summari
demonstr
sirna
homolog
fiv
gag
gene
effici
inhibit
replic
fiv
fibroblast
cell
chronic
infect
fiv
moreov
show
retroviru
vectormedi
transfer
fivspecif
shrna
could
inhibit
replic
fiv
lymphoid
cell
chronic
infect
fiv
present
studi
indic
rnai
technolog
use
gene
therapi
strategi
control
fiv
infect
